FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

Slides:

Advertisements

Similar presentations

Mary Ellen Turner MD, MPH Vice-President

Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

5th Annual PBM Pharmacy Informatics Conference

Dr. John E. Niederhuber Director, National Cancer Institute Board of Scientific Advisors June 22, 2009 NCI Director’s Update.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Assessing the Safety of Marketed Drugs Current Issues and Controversies Captain Paul J. Seligman, M.D., MPH Associate Director, Safety Policy and Communication.

Oregon EPC DRUG EFFECTIVENESS REVIEW PROJECT Methods for Comparative Evidence Reviews September 2005 Oregon Evidence-based Practice Center for the Drug.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

Special Topics in IND Regulation

Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.

Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

1 Drug Safety Oversight Board Update DIA Annual Meeting Philadelphia, PA June 21 st, 2006 Susan K. Cummins, MD, MPH Executive Director Drug Safety Oversight.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

1 Regulatory Concepts for Dual Indication Combination Products Charu Mullick, M.D. Division of Antiviral Products, CDER U.S. Food and Drug Administration.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

Regulation of Promotion of Prescription Drugs Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

1 Medical Device Safety Susan Gardner, Ph.D. Director, Office of Surveillance and Biometrics Center for Devices and Radiological Health.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

1 Regulatory History of OTC Phenylpropanolamine Hydrochloride (PPA) Robert L. Sherman Division of OTC Drug Products Center for Drug Evaluation and Research.

Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

FDA’s Draft LDT Framework & Personalized Medicine Update

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

1Presentation Name Pre-Marketing Safety Assessment: The Safety Review Guidance Armando Oliva, M.D. Associate Director for Policy Office of New Drugs.

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

Orlistat 60 mg Joint Meeting Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees January 23, 2006 Andrea Leonard-Segal, M.D.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

FDA Regulation of Prescription Drug Promotion Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

History of Pediatric Labeling

CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.

Medicaid and the Effective Health Care Program William Lawrence, MD, MS Center for Outcomes and Evidence.

A-1 Introduction Pravastatin-Aspirin 7asdf Fred T. Fiedorek, M.D. Vice President, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute.

Introducing RADAR: The Research on Adverse Drug Events And Reports (RADAR) Project Charles L. Bennett MD, PhD, MPP Feinberg School of Medicine, Northwestern.

1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.

Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

Office of Drug Safety Updates Drug Safety and Risk Management Advisory Committee Meeting February 10, 2006 Gerald J. Dal Pan, MD, MHS Director, Office.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Update on Current FDA Labeling Initiatives Iris P. Masucci, PharmD, BCPS Center for Drug Evaluation and Research FDA November 16, 2006 Pediatric Advisory.

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.

Chapter Legislative Representatives Government Affairs Update April 2014.

1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA.

Risk Management, Risk Communication, and Drug Safety: The U.S. Experience Geoffrey Levitt Chief Regulatory Counsel Wyeth August 23, 2007.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.

1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks.

Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.

Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.

Clinical Trials.

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

Innovation and the Pharmaceutical Research and Development Industry January 2002 MSD South Africa.

FDA’s IDE Decisions and Communications

Clinical Trials — A Closer Look

FDA Perspective on Cardiovascular Device Development

FDA-CDRH in the Next Decade A Vision for Change

Presentation transcript:

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food and Drug Administration

November 6, Outline Review of last spring Science Board mtg External studies/Investigations underway Internal policy changes & development Drug Watch guidance and comments Involving the public and expert peer reviewers Drug safety budget, personnel and organization DSOB and early communication examples – Dr. Throckmorton Q & A

November 6, Spring 2005 Science Board Briefing on Drug Safety Pre-Market Drug Safety: Labeling and Electronic Initiatives: Drug Safety Initiatives: Post-Market Drug Safety: Drug Safety Resources: Applying New Science to Drug Safety: Committee Questions and Discussion

November 6, Key Points from Spring Meeting 50 % of CDER resources spent on drug safety – every office, most activities Many new initiatives underway to improve: pre and post-market analysis & communication Fundamental progress in drug safety will be made only with continued scientific investments and scientific progress

November 6, 2005 Example: New Technologies for Personalized Medicine Genomic, proteomic, metabolomic markers Status in patients with serious side effects vs those without? Study in prospective trials and from MedWatch reports Develop ability to avoid high risk patients or monitor for development before overt toxicity occurs

November 6, External studies/Investigations Underway Institute of Medicine General Accounting Office/ US Congress Open Congressional Investigations

November 6, Progress Underway: Internal policy changes & development SOPs on interactions between CDER units Quality Systems implementation and process improvements New communications paradigms – DT DSOB, “sheets”, adverse events newsletter

November 6, Proposed Drug Watch Draft Guidance Many comments Support for early communication but unfavorable comments about Watch Collating/ summarizing Policy to be revised, as appropriate

November 6, Public comment & expert peer review “Part 15” Hearings: Risk Communication and Direct-to-Consumer Advertising Survey of physicians preferences on risk communications Drug Safety and Risk Management Advisory Committee: May 18-19, 2005 Discuss drugs safety issues including Risk assessment program for marketed drugs Advantages/Disadvantages of current system

November 6, Advisory Committee Meetings Anti-viral: HIV, chronic hepatitis B Arthritis: severe rheumatoid arthritis Cardiovascular: treatment of heart failure Dermatologic/Opthalmic with Nonprescription: Rx to OTC switch of corticosteroids Endocrinologic and Metabolic: type II diabetes mellitus Nonprescription: benefits/risks of antibacterial soaps

November 6, Advisory Committee Meetings Oncologic: transfusion dependent anemia, leukemia, prostate cancer Pediatric: discussed pediatric post-marketing studies for products for cancer indications Peripheral and Central Nervous System: migraines Pharmaceutical Science: assessment of research programs, quality by design Psychopharmacologic: major depressive disorder, need for longer term efficacy data Pulmonary-Allergy: asthma, COPD, preventing rejection of lung transplant

November 6, Drug Safety Budget, Personnel and Organization FY 2006 House/Senate Conference Report: House proposes additional $5M for drug safety activities over original $5M drug safety increase request (for total of $10M) New Director of Office of Drug Safety – Gerald DalPan, MD, MHS New Reorganization Plan for CDER

November 6, Reorganization: Goals Reflect the commitment of CDER to sustained, multi-disciplinary, cross-Center approach to drug safety Placement in organization must reflect level of commitment Need focus and consistency and improvement in communication about drug risks and benefits Need focus for cross-center policy development Locus for Critical Path Activities

November 6, Reorganization: Proposal New Associate Center Director – drug safety policy and risk communication focus Consolidate certain communications activities Elevated organizational status unit responsible for epidemiology and surveillance (current Office of Drug Safety) Report to Center Director New “super-office” combining OCPB, OB, responsible for CP projects and other cross-cuttting science activities

November 6, Summary Continued high level of focus on improving drug safety and risk communications activities in CDER while outside evaluations conclude with recommendations

November 6, Drug Safety Oversight Board Update Doug Throckmorton, MD